Physician profile
Lionel Dsouza
NPI 1679733182
$70,019.99
in general payments reported to CMS, 2019-2025
35 companies · $4,046 in 2025
The $4,046 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,249 · 2020: $431 · 2021: $2,046 · 2022: $3,196 · 2023: $12K · 2024: $45K · 2025: $4,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,438 · Food and Beverage: $6,758 · Travel and Lodging: $6,514 · Education: $29.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,358.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,437.50 |
| Food and Beverage | $6,757.73 |
| Travel and Lodging | $6,513.99 |
| Education | $29.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38,158.49 | 2019-2025 | Resolution 360 Clip, Axios, General - Therapies |
| Creo Medical INC. | $12,265.60 | 2021-2024 | Speedboat Ultraslim (Sb1l), Speedboat |
| Olympus America INC. | $10,266.31 | 2019-2025 | Visiglide, Disposable Grasping Forceps, Endoclot Sis |
| Abbvie INC. | $1,733.17 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Steris Corporation | $942.36 | 2019-2024 | |
| Covidien Lp | $913.52 | 2019 | |
| Olympus Medical Systems Corporation | $825.00 | 2025 | |
| Olympus Corporation of The Americas | $790.14 | 2021-2024 | Visiglide |
| Conmed Corporation | $727.89 | 2019-2025 | Conmed Biliary |
| Medtronic, INC. | $678.62 | 2022-2025 | Endoflip, Nexpowder, Prodigi |
| 3-D Matrix, INC. | $429.86 | 2024-2025 | |
| Cook Medical LLC | $354.11 | 2019-2025 | Fusion, Echotip Insight |
| Ferring Pharmaceuticals INC. | $261.31 | 2019-2023 | Rebyota |
| Endogastric Solutions, INC | $246.11 | 2019-2024 | Esophyx |
| Takeda Pharmaceuticals U.S.A., INC. | $195.10 | 2019-2024 | Entyvio, Gattex |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $129.50 | 2025 | Esophyx |
| Apollo Endosurgery US INC | $126.00 | 2022 | |
| Pentax of America, INC. | $125.15 | 2022-2023 | C2 Cryoballoon |
| Ironwood Pharmaceuticals, INC | $124.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $110.79 | 2021 | |
| Janssen Biotech, INC. | $105.03 | 2024 | Stelara |
| Phathom Pharmaceuticals, INC. | $77.84 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $76.71 | 2022-2024 | Terlivaz |
| Lilly USA, LLC | $61.20 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $40.23 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.31 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $31.31 | 2019 | |
| Gilead Sciences, INC. | $29.77 | 2024 | Livdelzi |
| Pfizer INC. | $29.39 | 2019 | |
| Celltrion USA INC. | $29.12 | 2024 | Zymfentra |
| Shire North American Group INC | $24.58 | 2019 | |
| Exact Sciences Corporation | $21.88 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $21.13 | 2022 | |
| Celgene Corporation | $17.25 | 2023 | Zeposia |
| Alnylam Pharmaceuticals INC. | $16.25 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lionel Dsouza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.